MedCity News January 5, 2023
Fewer new drugs won FDA approvals in 2022 compared to previous years, but some of the products that passed regulatory muster are indicative of trends expected to continue into 2023. For example, more gene and cell therapies are on track to face regulatory decisions in the coming year.
Cancer drug research is producing more targeted therapies that address particular genetic signatures. Last year saw a fair share of new targeted cancer therapies, but 2022 was also notable for the expansion of genetic insights beyond oncology. Three gene therapies won FDA approval and the growing list of such therapies in clinical testing suggests the trend will continue this year.
The three newly approved gene therapies are among the 42 drugs and...
Today's Sponsors
Today's Sponsor